Understanding the Burdens of Illness and Treatment in Severe Leukocyte Adhesion Deficiency Type I (LAD-I): Results from a Multi-Case Study with Caregivers

Le résumé fourni par la source

Background Leukocyte adhesion deficiency type I (LAD-I) is a rare inborn error of immunity affecting approximately 1 in 1 million individuals worldwide. Severe LAD-I is characterized by frequent life-threatening infections and significant pediatric mortality. Although this can have devastating effects on children and their families, there is little research about the lived experience of the disease. To fill this gap, we executed a multi-case study to describe the burden of severe LAD-I from the caregiver perspective. Methods Caregivers from 5 families with children with severe LAD-I participated in individual, in-depth interviews. Interviews followed a study-specific guide using concept and photo elicitation to obtain descriptions of caring for a child with severe LAD-I. Interview transcripts were analyzed using inductive and deductive approaches to describe the burdens of illness and treatment. Results Nine parents were interviewed. Among the 7 children, treatments included: allogeneic hematopoietic stem cell transplantation (alloHSCT; n = 2), investigational gene therapy (GT; n = 4), and antimicrobial prophylaxis (n = 1). Findings were organized under themes of burden of illness and burden of treatment (Table 1). The burden of illness included challenging journeys to diagnosis and frequent, hard-to-treat infections, leading children and caregivers to isolate physically and socially to reduce infection risk. All caregivers rearranged their jobs or career trajectories substantially to accommodate caregiving. Most parents were frustrated by the absence of LAD-I–specific resources and information. The burden of treatment differed by therapy. AlloHSCT families described difficult recoveries and, for 1 child, only partial success in treating LAD-I. GT families experienced a significant reduction of burden of illness, yet some expressed concerns for their child’s future given the novelty of the treatment. All participants agreed that antimicrobials were not a long-term treatment solution. Table 1.Main themes within burden of illness and treatment in severe LAD-I.BurdenThemesExamplesIllnessFrequent and varied infectionsRashes, skin/mucosal lesions, and infections in the lungs, ears, gums; poorly healing umbilical cordsPhysical restrictionsAvoiding water parks, beaches, other outdoor activities; limiting sports; preventing contact with petsSocial restrictionsLimiting visitors to the home; avoiding daycare; home schoolingJourney to diagnosis marked by lack of informationFailure of frequent severe infections and slow healing wounds to drive investigation and diagnosis; lack of resources, guidance, and information pre- and post-diagnosisTreatmentAlloHSCTSearching for a bone marrow match; complexity of alloHSCT process; managing alloHSCT complications; side-effects from post-transplant treatments; waning efficacyGene therapyGenerally positive outcomes, despite a long and complex process; required relocation for the duration of treatment; uncertainty about durability and longer-term effects given the novelty of GTProphylactic antimicrobialsIn 1 case, in the absence of a family donor match for alloHSCT, the clinician recommended this approach; parents indicated it is not a long-term nor complete solution Conclusion Together, the burdens of illness and treatment had profound impacts on these families. The parents’ descriptions also demonstrated that while none of the current treatments for severe LAD-I is perfect, GT shows great potential for improving patients’ health and minimizing disease burden. Moreover, this research provides critical insights for clinicians, whose care of children with severe LAD-I can be informed by understanding the struggles associated with the burdens of illness and treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.